Paper No. 22 Filed: November 15, 2019

## UNITED STATES PATENT AND TRADEMARK OFFICE

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

MYLAN PHARMACEUTICALS INC., SAWAI USA, INC., AND SAWAI PHARMACEUTICAL CO., LTD., Petitioner,

v.

BIOGEN MA INC., Patent Owner.

\_\_\_\_\_

IPR2019-00789<sup>1</sup> Patent 8,399,514 B2

\_\_\_\_\_

Before ANDREI IANCU, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, ANDREW HIRSHFELD, Commissioner for Patents, and SCOTT R. BOALICK, Chief Administrative Patent Judge.

PER CURIAM.

**ORDER** 

<sup>&</sup>lt;sup>1</sup> IPR2019-00789 is joined to IPR2018-01403.



IPR2019-00789 Patent 8,399,514 B2

The Office received a request for Precedential Opinion Panel (POP) review of an issue raised in this case. *See* Ex. 3001. The request was referred to the POP panel referenced above.

Upon consideration of the request, it is

ORDERED that the request for POP review is denied; and

FURTHER ORDERED that the original panel maintains authority over all matters, including considering the submitted rehearing request.



IPR2019-00789 Patent 8,399,514 B2

For PETITIONER:

Brian Sodikoff
Brian.sodikoff@kattenlaw.com

Christopher Ferenc @kattenlaw.com

Martin S. Masar III martin.masar@katten.com

For PATENT OWNER:

Barbara McCurdy Barbara.mccurdy@finnegan.com

Mark Feldstein

Mark.feldstein@finnegan.com

Erin Sommers
Erin.sommers@finnegan.com

Pier DeRoo Pier.deroo@finnegan.com

